1
|
Grammes J, Schmid S, Bozkurt L, Heinemann L, Hess G, Kubiak T, Küstner E, Priesterroth LS, Stahl C, Holl RW. Continuous glucose monitoring in older adults with diabetes: Data from the diabetes prospective follow-up (DPV) registry. Diabet Med 2024; 41:e15261. [PMID: 38009855 DOI: 10.1111/dme.15261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Revised: 11/10/2023] [Accepted: 11/15/2023] [Indexed: 11/29/2023]
Abstract
AIMS To analyse predictors for continuous glucose monitoring (CGM) use in people with diabetes aged ≥60 years using insulin therapy and to assess the rates of CGM use during recent years (2019-2021). RESEARCH DESIGN AND METHODS Prospective study including 6849 individuals with diabetes and insulin therapy (type 2 diabetes: n = 5320; type 1 diabetes: n = 1529) aged ≥60 years. Data from 129 treatment centres were retrieved from the Diabetes Prospective Follow-up Registry (DPV) in March 2023. RESULTS Sensor use in individuals aged ≥60 years has increased in type 1 (2019: 28%, 2020: 39%, 2021: 45%) and type 2 diabetes (2019: 10%, 2020: 16%, 2021: 18%). Predictors for sensor use in older individuals with type 1 diabetes are younger age and CSII use (p < 0.001). Predictors in older individuals with type 2 diabetes are younger age, longer diabetes duration, higher BMI and CSII use (p < 0.001). CONCLUSIONS CGM has become more common in older adults with diabetes and will presumably increase further. Age is a predictor for sensor use in older adults with diabetes. Age-related physical barriers and insufficient usability of devices, lack of interest in technologies, but possibly also effects of prejudice on the grounds of age may contribute to this finding.
Collapse
Affiliation(s)
- Jennifer Grammes
- Health Psychology, Johannes Gutenberg University, Mainz, Germany
| | - Stefanie Schmid
- Institute of Epidemiology and Medical Biometry, CAQM, University of Ulm, Ulm, Germany
- German Center for Diabetes Research (DZD), Munich, Germany
| | - Latife Bozkurt
- Department of Internal Medicine III and Karl Landsteiner Institute for Metabolic Disorders and Nephrology, Clinic Hietzing, Vienna Health Care Group, Vienna, Austria
| | | | - Gregor Hess
- Diabetology Private Practice, Worms, Germany
| | - Thomas Kubiak
- Health Psychology, Johannes Gutenberg University, Mainz, Germany
| | | | | | | | - Reinhard W Holl
- Institute of Epidemiology and Medical Biometry, CAQM, University of Ulm, Ulm, Germany
- German Center for Diabetes Research (DZD), Munich, Germany
| |
Collapse
|
2
|
Korenblik R, van Zon JFJA, Olij B, Heil J, Dewulf MJL, Neumann UP, Olde Damink SWM, Binkert CA, Schadde E, van der Leij C, van Dam RM, van Baardewijk LJ, Barbier L, Binkert CA, Billingsley K, Björnsson B, Andorrà EC, Arslan B, Baclija I, Bemelmans MHA, Bent C, de Boer MT, Bokkers RPH, de Boo DW, Breen D, Breitenstein S, Bruners P, Cappelli A, Carling U, Robert MCI, Chan B, De Cobelli F, Choi J, Crawford M, Croagh D, van Dam RM, Deprez F, Detry O, Dewulf MJL, Díaz-Nieto R, Dili A, Erdmann JI, Font JC, Davis R, Delle M, Fernando R, Fisher O, Fouraschen SMG, Fretland ÅA, Fundora Y, Gelabert A, Gerard L, Gobardhan P, Gómez F, Guiliante F, Grünberger T, Grochola LF, Grünhagen DJ, Guitart J, Hagendoorn J, Heil J, Heise D, Herrero E, Hess G, Hilal MA, Hoffmann M, Iezzi R, Imani F, Inmutto N, James S, Borobia FJG, Jovine E, Kalil J, Kingham P, Kollmar O, Kleeff J, van der Leij C, Lopez-Ben S, Macdonald A, Meijerink M, Korenblik R, Lapisatepun W, Leclercq WKG, Lindsay R, Lucidi V, Madoff DC, Martel G, Mehrzad H, Menon K, Metrakos P, Modi S, Moelker A, Montanari N, Moragues JS, Navinés-López J, Neumann UP, Nguyen J, Peddu P, Primrose JN, Olde Damink SWM, Qu X, Raptis DA, Ratti F, Ryan S, Ridouani F, Rinkes IHMB, Rogan C, Ronellenfitsch U, Serenari M, Salik A, Sallemi C, Sandström P, Martin ES, Sarría L, Schadde E, Serrablo A, Settmacher U, Smits J, Smits MLJ, Snitzbauer A, Soonawalla Z, Sparrelid E, Spuentrup E, Stavrou GA, Sutcliffe R, Tancredi I, Tasse JC, Teichgräber U, Udupa V, Valenti DA, Vass D, Vogl TJ, Wang X, White S, De Wispelaere JF, Wohlgemuth WA, Yu D, Zijlstra IJAJ. Resectability of bilobar liver tumours after simultaneous portal and hepatic vein embolization versus portal vein embolization alone: meta-analysis. BJS Open 2022; 6:6844022. [PMID: 36437731 PMCID: PMC9702575 DOI: 10.1093/bjsopen/zrac141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Revised: 09/09/2022] [Accepted: 10/05/2022] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND Many patients with bi-lobar liver tumours are not eligible for liver resection due to an insufficient future liver remnant (FLR). To reduce the risk of posthepatectomy liver failure and the primary cause of death, regenerative procedures intent to increase the FLR before surgery. The aim of this systematic review is to provide an overview of the available literature and outcomes on the effectiveness of simultaneous portal and hepatic vein embolization (PVE/HVE) versus portal vein embolization (PVE) alone. METHODS A systematic literature search was conducted in PubMed, Web of Science, and Embase up to September 2022. The primary outcome was resectability and the secondary outcome was the FLR volume increase. RESULTS Eight studies comparing PVE/HVE with PVE and six retrospective PVE/HVE case series were included. Pooled resectability within the comparative studies was 75 per cent in the PVE group (n = 252) versus 87 per cent in the PVE/HVE group (n = 166, OR 1.92 (95% c.i., 1.13-3.25)) favouring PVE/HVE (P = 0.015). After PVE, FLR hypertrophy between 12 per cent and 48 per cent (after a median of 21-30 days) was observed, whereas growth between 36 per cent and 67 per cent was reported after PVE/HVE (after a median of 17-31 days). In the comparative studies, 90-day primary cause of death was similar between groups (2.5 per cent after PVE versus 2.2 per cent after PVE/HVE), but a higher 90-day primary cause of death was reported in single-arm PVE/HVE cohort studies (6.9 per cent, 12 of 175 patients). CONCLUSION Based on moderate/weak evidence, PVE/HVE seems to increase resectability of bi-lobar liver tumours with a comparable safety profile. Additionally, PVE/HVE resulted in faster and more pronounced hypertrophy compared with PVE alone.
Collapse
Affiliation(s)
- Remon Korenblik
- Correspondence to: R. K., Universiteigssingel 50 (room 5.452) 6229 ER Maastricht, The Netherlands (e-mail: ); R. M. v. D., Maastricht UMC+, Dept. of Surgery, Level 4, PO Box 5800, 6202 AZ Maastricht, The Netherlands (e-mail: )
| | - Jasper F J A van Zon
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Bram Olij
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands,GROW—Department of Surgery, School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands,Department of General, Visceral and Transplant Surgery, University Hospital RWTH Aachen, Aachen, Germany
| | - Jan Heil
- Department of General, Visceral and Transplant Surgery, University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany
| | - Maxime J L Dewulf
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Ulf P Neumann
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands,Department of General, Visceral and Transplant Surgery, University Hospital RWTH Aachen, Aachen, Germany
| | - Steven W M Olde Damink
- Department of Surgery, Maastricht University Medical Center, Maastricht, The Netherlands,Department of General, Visceral and Transplant Surgery, University Hospital RWTH Aachen, Aachen, Germany,NUTRIM—Department of Surgery, School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands
| | - Christoph A Binkert
- Department of Radiology, Cantonal Hospital Winterthur, Winterthur, Switzerland
| | - Erik Schadde
- Department of General, Visceral and Transplant Surgery, Klinik Hirslanden, Zurich, Switzerland,Department of General, Visceral and Transplant Surgery, Hirslanden Klink St. Anna Luzern, Luzern, Switzerland
| | | | - Ronald M van Dam
- Correspondence to: R. K., Universiteigssingel 50 (room 5.452) 6229 ER Maastricht, The Netherlands (e-mail: ); R. M. v. D., Maastricht UMC+, Dept. of Surgery, Level 4, PO Box 5800, 6202 AZ Maastricht, The Netherlands (e-mail: )
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Novak U, Fehr M, Schär S, Dreyling M, Scheubeck G, Ramadan S, Zucca E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Menter T, Dirnhofer S, Gadient S, Eckhardt K, Driessen C, Renner C. SAKK 36/13 ‐ IBRUTINIB PLUS BORTEZOMIB AND IBRUTINIB MAINTENANCE FOR RELAPSED AND REFRACTORY MANTLE CELL LYMPHOMA: FINAL REPORT OF A PHASE I/II TRIAL OF THE EUROPEAN MCL NETWORK. Hematol Oncol 2021. [DOI: 10.1002/hon.62_2879] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- U. Novak
- Inselspital, Bern University Hospital Medical Oncology Bern Switzerland
| | - M. Fehr
- Kantonsspital St. Gallen Department of Medical Oncology and Hematology St. Gallen Switzerland
| | - S. Schär
- SAKK Coordinating Center Bern Switzerland
| | - M. Dreyling
- Universität München‐Grossadern Medizinische Klinik III München Germany
| | - G. Scheubeck
- Universität München‐Grossadern Medizinische Klinik III München Germany
| | - S. Ramadan
- IEO, European Institute of Oncology IRCCS Onco‐Hematology Division Milano Italy
| | - E. Zucca
- Oncology Institute of Southern Switzerland Ospedale San Giovanni Bellinzona Switzerland
| | - T. Zander
- Kantonsspital Luzern Department Oncology Luzern Switzerland
| | - G. Hess
- Johannes Gutenberg Universität Mainz Universitätsmedizin Mainz Germany
| | - U. Mey
- Kantonsspital Graubünden Department of Oncology and Hematology Chur Switzerland
| | - S. Ferrero
- AOU "Città della Salute e della Scienza di Torino" Hematology 1 Torino Italy
| | - N. Mach
- University Hospital of Geneva Department of Oncology Genève Switzerland
| | - C. Boccomini
- AOU "Città della Salute e della Scienza di Torino" Hematology 1 Torino Italy
| | - S. Böttcher
- Rostock University Medical Center Department of Medicine, Clinic III ‐ Hematology, Oncology Palliative Medicine Rostock Germany
| | - M. Voegeli
- Kantonsspital Baselland Oncology Liestal Switzerland
| | - A. Cairoli
- CHUV University Hospital and University of Lausanne Service et Laboratoire Central d'Hématologie Département d'Oncologie Lausanne Switzerland
| | - T. Menter
- University Hospital Basel Institute of Pathology and Medical Genetics Basel Switzerland
| | - S. Dirnhofer
- University Hospital Basel Institute of Pathology and Medical Genetics Basel Switzerland
| | - S. Gadient
- SAKK Coordinating Center Bern Switzerland
| | | | - C. Driessen
- Kantonsspital St. Gallen Department of Medical Oncology and Hematology St. Gallen Switzerland
| | - C. Renner
- Onkozentrum, Hirslanden & Zürich Zürich Switzerland
| |
Collapse
|
4
|
Popek M, Bobula B, Sowa J, Hess G, Frontczak-Baniewicz M, Albrecht J, Zielińska M. Physiology and Morphological Correlates of Excitatory Transmission are Preserved in Glutamine Transporter SN1-Depleted Mouse Frontal Cortex. Neuroscience 2020; 446:124-136. [DOI: 10.1016/j.neuroscience.2020.08.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2020] [Revised: 07/16/2020] [Accepted: 08/14/2020] [Indexed: 01/22/2023]
|
5
|
Fürstenau M, Bahlo J, Fink AM, Lange E, Dreger P, Dreyling M, Hess G, Ritgen M, Kneba M, Döhner H, Stilgenbauer S, Wendtner CM, Goede V, Fischer K, Böttcher S, Hallek M, Eichhorst B. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia 2019; 34:924-928. [PMID: 31611627 DOI: 10.1038/s41375-019-0597-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 08/30/2019] [Accepted: 09/30/2019] [Indexed: 11/10/2022]
Affiliation(s)
- M Fürstenau
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| | - J Bahlo
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - A M Fink
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - E Lange
- Evangelisches Krankenhaus Hamm, Hamm, Germany
| | - P Dreger
- Department of Medicine V, University Hospital Heidelberg, Heidelberg, Germany
| | - M Dreyling
- Department of Internal Medicine III, University Hospital of the Ludwig Maximilians University Munich, Munich, Germany
| | - G Hess
- Department of Hematology, Medical Oncology and Pneumology, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany
| | - M Ritgen
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - M Kneba
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany
| | - H Döhner
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
| | - S Stilgenbauer
- Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany.,Department of Hematology, Oncology and Rheumatology and José Carreras Center for Immuno and Gene Therapy, Saarland University Medical School, Homburg/Saar, Germany
| | - C M Wendtner
- Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, München Klinik Schwabing, Munich, Germany
| | - V Goede
- Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany
| | - K Fischer
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany
| | - S Böttcher
- Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany.,Medical Clinic III, Hematology, Oncology and Palliative Medicine, Rostock University Medical Center, Rostock, Germany
| | - M Hallek
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.,Cologne Cluster of Excellence in Cellular Stress Responses in Aging-associated Disease (CECAD), University of Cologne, Cologne, Germany
| | - B Eichhorst
- Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, German CLL Study Group, University Hospital Cologne, University of Cologne, Cologne, Germany.
| |
Collapse
|
6
|
Viardot A, Hess G, Bargou R, Morley N, Gritti G, Iskander K, Cohan D, Zhang A, Franklin J, Coyle L. DURABILITY OF COMPLETE RESPONSE AFTER BLINATUMOMAB THERAPY FOR REFRACTORY/RELAPSED AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA. Hematol Oncol 2019. [DOI: 10.1002/hon.102_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- A. Viardot
- Department of Internal Medicine; University Hospital of Ulm; Ulm Germany
| | - G. Hess
- Department of Hematology; Oncology and Pneumology, Johannes Gutenberg-University; Mainz Germany
| | - R. Bargou
- Comprehensive Cancer Center Mainfranken; Würzburg University Medical Center; Würzburg Germany
| | - N.J. Morley
- Haematology; Royal Hallamshire Hospital; Sheffield United Kingdom
| | - G. Gritti
- UOC Ematologia; Ospedale Papa Giovanni XXIII; Bergamo Italy
| | - K. Iskander
- Global Medical Organization; Amgen Inc.; Thousand Oaks United States
| | - D. Cohan
- Global Medical Organization; Amgen Inc.; Thousand Oaks United States
| | - A. Zhang
- Global Medical Organization; Amgen Inc.; Thousand Oaks United States
| | - J. Franklin
- Global Medical Organization; Amgen Inc.; Thousand Oaks United States
| | - L. Coyle
- Haematology; Royal Northshore Hospital; St Leonards Australia
| |
Collapse
|
7
|
Dreyling M, Hess G, Woike M, Krekeler G. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy286.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
8
|
Rule S, Jurczak W, Jerkeman M, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32:1799-1803. [PMID: 29572505 PMCID: PMC6087720 DOI: 10.1038/s41375-018-0023-2] [Citation(s) in RCA: 63] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2017] [Revised: 11/21/2017] [Accepted: 12/22/2017] [Indexed: 11/23/2022]
Affiliation(s)
- S Rule
- Plymouth University Medical School, Plymouth, UK.
| | - W Jurczak
- Department of Hematology, Jagiellonian University, Krakow, Poland
| | - M Jerkeman
- Skånes University Hospital, Lund University, Lund, Sweden
| | - C Rusconi
- Hematology Division, Hematology and Oncology Department, Niguarda Cancer Center, Niguarda Hospital, Milan, Italy
| | - M Trneny
- Ist Dept Medicine, Charles University General Hospital, Prague, Czech Republic
| | - F Offner
- Departement Oncologie, UZ Gent, Ghent, Belgium
| | - D Caballero
- Instituto Biosanitario de Salamanca, Hospital Clinico Universitario Salamanca, Salamanca, Spain
| | - C Joao
- Institutto Português de Oncologia de Lisboa, Portugal and Champalimaud Centre for the Unknown, Hematology, Lisbon, Portugal
| | - M Witzens-Harig
- Klinikum der Ruprechts-Karls-Universität Heidelberg, Med. Klinik u. Poliklinik V, Heidelberg, Germany
| | - G Hess
- Department of Hematology, Oncology and Pneumology, University Medical School of the Johannes Gutenberg University, Mainz, Germany
| | | | - S-G Cho
- Seoul St. Mary's Hospital, Seocho-gu, Seoul, South Korea
| | - C Thieblemont
- APHP, Saint-Louis Hospital, Hemato-oncology, Diderot University, Paris, France
| | - W Zhou
- Janssen Research & Development, Raritan, NJ, USA
| | - T Henninger
- Janssen Research & Development, Raritan, NJ, USA
| | - J Goldberg
- Janssen Research & Development, Raritan, NJ, USA
| | - J Vermeulen
- Janssen Research & Development, Leiden, The Netherlands
| | - M Dreyling
- Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany
| |
Collapse
|
9
|
Hess G, Mehra R, Carls G, Profant J, Altenburger J, Pasenchenko O, Acquavella JF. 0625 US Prevalence of Narcolepsy and Other Sleep Disorders From 2013–2016: A Retrospective, Epidemiological Study Utilizing Nationwide Claims. Sleep 2018. [DOI: 10.1093/sleep/zsy061.624] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G Hess
- Scientific Studies & Projects Group, Symphony Health, Conshohocken, PA
- Institute of Health Economics, University of Pennsylvania, Philadelphia, PA
| | - R Mehra
- Neurologic Institute, Cleveland Clinic, Cleveland, OH
| | - G Carls
- Medical Affairs, Jazz Pharmaceuticals, Inc., Palo Alto, CA
| | - J Profant
- Medical Affairs, Jazz Pharmaceuticals, Inc., Palo Alto, CA
| | - J Altenburger
- Business Intelligence, Jazz Pharmaceuticals, Inc., Palo Alto, CA
| | - O Pasenchenko
- Scientific Studies & Projects Group, Symphony Health, Conshohocken, PA
| | - J F Acquavella
- Department of Clinical Epidemiology, Aarhus University, Aarhus, DENMARK
- International Society for Pharmacoepidemiology, Bethesda, MD
| |
Collapse
|
10
|
Sheng L, Soumillion A, Peerlinck K, Verslype C, Schelstraete R, Gyselinck F, Emonds MP, Hess G, Vermylen J, Desmyter J, Yap SH. Anti-hepatitis G E2 Antibody Detection and Its Relation to Serum HGV-RNA in Patients with Clotting Disorders: High Prevalence of HGV Infection and Spontaneous Remission. Thromb Haemost 2017. [DOI: 10.1055/s-0037-1615059] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
SummaryIn a previous study, we have determined the prevalence of serum HGV-RNA in patients with congenital clotting disorders. Twenty-six (15%) of 175 patients investigated were serum HGV-RNA positive. In addition, HGV-RNA was detectable in peripheral blood mononuclear cells (PBMC) in ten percent of the cases, three of these patients were serum HGV-RNA negative.In the present study, we have determined the prevalence of anti-HGV-E2 antibodies in the same patient population. Anti-HGV-E2 as determined by ELISA was detected in 45 patients (25.7%). Forty of these patients were serum HGV-RNA negative.Ninety-two percent of the 26 HGV viremic patients and all but one patient (44 patients) with detectable anti-HGV-E2 had coinfection with the hepatitis C virus (HCV). Of these coinfected patients, 62.5% of HGV viremic patients and 53% of anti-HGV-E2 positive patients showed elevated serum ALT levels. Anti-HGV-E2 seroconversion is thus not associated with HCV infection. Two patients who were solely infected with HGV had normal serum ALT levels. In a retrospective longitudinal study, we have observed in 15 patients that serum HGV-RNA persisted during one to 19 years of follow-up, while anti-HGV-E2 was repeatedly negative. Five additional patients who were anti-HGV-E2 positive with concomitant detectable HGV-RNA (4 patients in serum and 1 patient in PBMC) became HGV-RNA negative during follow-up, ranging from 1 to 8 years after the first detection of anti-HGV-E2 antibodies. Two patients had lost anti-HGV-E2 antibodies 3 to 6 years after the seroconversion without the re-appearance of serum HGV-RNA. From these findings, it is clear that the prevalence rate of HGV infection in patients with clotting disorders as determined by PCR assay for HGV-RNA and anti-HGV-E2 by ELISA is actually higher than the prevalence of HGV viremia. Although HGV viremia may persist for longer than 19 years, most of the patients infected with HGV may clear the viremia spontaneously. The clearance of viremia is usually associated with seroconversion to anti-HGVE2. In addition, anti-HGV-E2 may be lost during years of follow-up without the reappearance of the HGV-RNA. Although HGV infection does not seem to influence the fate of HCV infection and does not induce increased levels of serum ALT, the clinical significance of long-term infection remains to be established.
Collapse
|
11
|
Dreyling M, Hess G, Krekeler G. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx373.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
12
|
Witzens-Harig M, Viardot A, Keller U, Buske C, Hönig E, Atta J, Larosee P, Marks R, Dreyling M, Hess G. SAFETY AND CLINICAL ACTIVITY OF TEMSIROLIMUS IN COMBINATION WITH RITUXIMAB AND DHAP IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA-REPORT OF THE PROSPECTIVE, MULTICENTER PHASE II STORM TRIAL. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_52] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- M. Witzens-Harig
- Hematology/Oncology; University of Heidelberg Hospital; Heidelberg Germany
| | - A. Viardot
- Hematology/Oncology; University of Ulm Hospital; Ulm Germany
| | - U. Keller
- III. Medical Department of Hematology and Medical Oncology; Technical University of Munich; Munich Germany
| | - C. Buske
- Hematology/Oncology; University of Ulm Hospital; Ulm Germany
| | - E. Hönig
- Interdisziplinäres Zentrum Klinische Studien (IZKS); Universitätsmedizin der Johannes Gutenberg-Universität Mainz; Mainz Germany
| | - J. Atta
- Hematology/Oncology; Tumortherapie Center; Offenbach Germany
| | - P. Larosee
- Klinik für Innere Medizin II: Onkologie, Hämatologie, Immunologie, Infektiologie und Palliativmedizin, Schwarzwald Baar Klinikum; Villingen-Schwenningen Germany
| | - R. Marks
- Hämatologie, Onkologie und Stammzelltransplantation, Klinik für Innere Medizin I; Freiburg Germany
| | - M. Dreyling
- Department of Internal Medicine III; Ludwig-Maximilians University of Munich; Munich Germany
| | - G. Hess
- III Medizinische Klinik; Universitätsmedizin Mainz; Mainz Germany
| |
Collapse
|
13
|
Rule S, Jurczak W, Jerkeman M, Santucci Silva R, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho S, Thieblemont C, Zhou W, Henninger T, Goldberg J, Vermeulen J, Dreyling M. IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- S. Rule
- Haematology; Derriford Hospital; Plymouth UK
| | - W. Jurczak
- Hematology; Jagiellonian University; Krakow Poland
| | - M. Jerkeman
- Oncology; Skånes University Hospital; Lund Sweden
| | - R. Santucci Silva
- Oncology; Instituto de Ensino e Pesquisa Sao Lucas; Sao Paulo Brazil
| | - C. Rusconi
- Hematology and Oncology; Niguarda Hospital; Milan Italy
| | - M. Trneny
- First Department Medicine; Charles University General Hospital; Prague Czech Republic
| | | | - D. Caballero
- Hematology; Hospital Clinico Universitario Salamanca; Salamanca Spain
| | - C. Joao
- Oncology; Institutto Português de Oncologia de Lisboa; Lisbon Portugal
| | | | - G. Hess
- Hematology, Oncology and Pneumology; University Medical School of the Johannes Gutenberg University; Mainz Germany
| | | | - S. Cho
- Hematology; Seoul St. Mary's Hospital; Seoul Republic of Korea
| | | | - W. Zhou
- Oncology; Janssen Research & Development; Raritan USA
| | - T. Henninger
- Oncology; Janssen Research & Development; Raritan USA
| | - J.D. Goldberg
- Oncology; Janssen Research & Development; Raritan USA
| | - J. Vermeulen
- Oncology; Janssen Research & Development; Beerse Belgium
| | - M. Dreyling
- Medicine III; Klinikum der Universität München, LMU; Munich Germany
| |
Collapse
|
14
|
Fowler N, Gopal A, Schuster S, Trotman J, Hess G, Hou J, Yacoub A, Lill M, Martin P, Vitolo U, Spencer A, Radford J, Jurczak W, Morton J, Osmanov D, Caballero D, Deshpande S, Vermeulen J, Damle R, Schaffer M, Balasubramanian S, Cheson B, Salles G. Biomarker analysis of patients with follicular lymphoma treated with ibrutinib in the phase 2 DAWN study. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_75] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- N. Fowler
- Department of Lymphoma/Myeloma; The University of Texas MD Anderson Cancer Center; Houston USA
| | - A.K. Gopal
- Seattle Cancer Care Alliance; The University of Washington/Fred Hutchison Cancer Research Center; Seattle USA
| | - S.J. Schuster
- Lymphoma Program; Abramson Cancer Center of the University of Pennsylvania; Philadelphia USA
| | - J. Trotman
- Concord Hospital; University of Sydney, Haematology Department; Sydney Australia
| | - G. Hess
- Department of Hematology/Oncology; Johannes Gutenberg University; Mainz Germany
| | - J. Hou
- Division of Hematology/Oncology; University of Pittsburgh Medical Center and University of Pittsburgh Cancer Institute; Pittsburgh USA
| | - A. Yacoub
- Hematologic Malignancies and Cellular Therapeutics; University of Kansas Medical Center; Kansas City USA
| | - M. Lill
- Stem Cell and Bone Marrow Transplant Program, Cedars-Sinai Medical Center; Los Angeles USA
| | - P. Martin
- Weill Cornell Medical College; Cornell University; New York USA
| | - U. Vitolo
- Hematology; Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino; Turin Italy
| | - A. Spencer
- Central Clinical School; Alfred Hospital-Monash University; Melbourne Australia
| | - J. Radford
- University of Manchester and the Christie NHS Foundation Trust; Manchester Academic Health Science Centre; Manchester UK
| | - W. Jurczak
- Department of Hematology; Jagiellonian University; Krakow Poland
| | - J. Morton
- Clinical Haemato-Oncology; Haematology and Oncology Clinics of Australia; Milton Australia
| | - D. Osmanov
- Blokhin Cancer Research Center; Russian Academy of Medical Sciences; Moscow Russian Federation
| | - D. Caballero
- Instituto Biosanitario de Salamanca; Hospital Clínico Universitario; Salamanca Spain
| | | | - J. Vermeulen
- Research & Development, Janssen; Leiden The Netherlands
| | - R. Damle
- Research & Development, Janssen; Raritan USA
| | - M. Schaffer
- Research & Development, Janssen; Raritan USA
| | | | - B. Cheson
- Lombardi Comprehensive Cancer Center; Georgetown University Hospital; Washington District of Columbia USA
| | - G. Salles
- Haematology Department; Hospices Civils de Lyon-Université de Lyon; Lyon France
| |
Collapse
|
15
|
Dreyling M, Krekeler G, Neuhof A, Woike M, Hess G, Kalanovic D. Evaluation of safety, tolerability and efficacy of temsirolimus in patients (pts) with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw375.25] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Kiss I, Rodón J, Pulido EG, Rha S, Sathornsumetee S, Hess G, Eigendorff E, Cesic D, Sutradhar S, Pramanik B, Kim T. Phase 2, open-label study of ceritinib in patients (pts) with advanced non-lung solid tumors and hematological malignancies characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK) using a flexible adaptive design: ASCEND-10. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.53] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Krekeler G, Neuhof A, Dreyling M, Hess G, Kalanovic D. 3221 Evaluation of safety, tolerability and efficacy of Temsirolimus in patients with relapsed or refractory mantle cell lymphoma (rel/refr MCL) in routine clinical practice. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31798-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
18
|
Hess G, Weber D, Kaltheuner M, Molinski M, Scheper N, Reuter HM, Heinemann L, Faber-Heinemann G. Zahngesundheit von Patienten die in Diabetes-Schwerpunktpraxen behandelt werden: Ein ignoriertes Problem? DIABETOL STOFFWECHS 2015. [DOI: 10.1055/s-0035-1549652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Kusek M, Sowa J, Tokarski K, Hess G. Impaired effect of activation of rat hippocampal 5-HT7 receptors, induced by treatment with the 5-HT7 receptor antagonist SB 269970. J Physiol Pharmacol 2015; 66:301-308. [PMID: 25903960] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Accepted: 02/09/2015] [Indexed: 06/04/2023]
Abstract
Effects of the 5-HT(7) receptor antagonist SB 269970, administered for 14 days (1.25 mg/kg), were studied in ex vivo slices of rat hippocampus. To activate the 5-HT(7) receptor, 5-carboxamidotryptamine (5-CT, 200 nM) was applied in the presence of WAY 100635 (2 μM), a 5-HT(1A) receptor antagonist. In contrast to control preparations, no 5-HT(7) receptor-mediated increase in excitability nor depolarization and an increase in the input resistance of CA1 and CA3 pyramidal neurons were present in slices prepared from rats treated with SB 269970. The treatment also abolished the stimulatory effect of 5-HT(7) receptor activation on spontaneous excitatory postsynaptic currents recorded from CA1 stratum radiatum/lacunosum-moleculare interneurons. These data demonstrate that repeated administration of SB 269970 impairs the reactivity of the CA1 hippocampal neuronal network to 5-HT(7) receptor activation.
Collapse
Affiliation(s)
- M Kusek
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.
| | | | | | | |
Collapse
|
20
|
Krekeler G, Dreyling M, Hess G, Kalanovic D. Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (Rel/Refr Mcl) in Routine Clinical Practice. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu339.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Redhardt A, Steinhoff HJ, Schütter J, Neumann HJ, Hess G. Higher Order Modes as Accuracy Limiting Factor in Permittivity Measurements of High Lossy Fluids Using Transmission Techniques in the GHz Range. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/zna-1989-0114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
The higher order mode distortion in measuring dielectric constants on high lossy, high permittivity liquids in the GHz range is investigated by a simulation procedure as well as by experiment. For this, a homodyne method for measuring ε* is introduced in analogy to precision EPR-work.
Collapse
Affiliation(s)
- A. Redhardt
- Institut für Biophysik der Ruhr-Universität Bochum
| | | | - J. Schütter
- Institut für Biophysik der Ruhr-Universität Bochum
| | | | - G. Hess
- Institut für Biophysik der Ruhr-Universität Bochum
| |
Collapse
|
22
|
Steinhoff HJ, Redhardt A, Lieutenant K, Chrost W, Hess G, Schlitter J, Neumann HJ. High Precision Measurements of the Permittivity of Water in the Microwave Range. ACTA ACUST UNITED AC 2014. [DOI: 10.1515/zna-1990-0515] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
A practical version of a homodyne method for measuring the complex permittivity of high loss liquids at 3 and 9 GHz is described. The systematic errors are discussed in detail, because the homodyne method seems to be suitable as a simple standard method for precise measurements. The results of measurements on water in the temperature range 6 °C-45 °C are presented. The determination of all five parameters of the Debye function is possible. Finally, accuracy limiting factors for the determination of the relaxation parameters are discussed in detail
Collapse
Affiliation(s)
- H. J. Steinhoff
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - A. Redhardt
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - K. Lieutenant
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - W. Chrost
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - G. Hess
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - J. Schlitter
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| | - H. J. Neumann
- Institut für Biophysik, Ruhr-Universität Bochum, 4630 Bochum, FRG
| |
Collapse
|
23
|
Weber D, Kaltheuner M, Scheper N, Hess G, Faber-Heinemann G, Heinemann L. Effekt von Schulung bei gleichzeitiger Umstellung einer medikamentösen Therapie: Daten von 648 Patienten die neu mit GLP-1-Analoga oder DPP-IV Inhibitoren in 38 Diabetes-Schwerpunktpraxen therapiert wurden. DIABETOL STOFFWECHS 2014. [DOI: 10.1055/s-0034-1375020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
24
|
Kopf S, Oikonomou D, von Eynatten M, Kieser M, Zdunek D, Hess G, Morcos M, Forsblom C, Bierhaus A, Groop PH, Nawroth PP, Humpert PM. Urinary excretion of high molecular weight adiponectin is an independent predictor of decline of renal function in type 2 diabetes. Acta Diabetol 2014; 51:479-89. [PMID: 24366425 DOI: 10.1007/s00592-013-0542-2] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/10/2013] [Accepted: 12/05/2013] [Indexed: 12/11/2022]
Abstract
Adiponectin and urinary adiponectin excretions have been ascribed a function in glomerular physiology and seem to indicate vascular disease in diabetes. The aim of this study was to compare the urinary excretion of albumin and adiponectin as predictors for decline of renal function in patients with type 2 diabetes and early kidney disease. Over 141 patients were screened for renal function (estimated GFR, ml/min*1.73 m(2)), albumin excretion rate (AER, mg/24 h), total as well as high molecular weight (HMW) urinary adiponectin excretion (ng/mol u-creatinine). AER and adiponectin excretion were studied as predictors of renal function after 1 year. After 1 year, 36 patients were in the upper quartile of eGFR decline and defined as progressors (delta eGFR = - 12.3 ± 6.3) while the remaining 105 patients were defined as non-progressors (delta eGFR = 1.4 ± 6.0). At baseline, HMW-adiponectin excretion was positively correlated with HbA1c (p < 0.001) and negatively with eGFR (p < 0.001), but not with AER (p = 0.14). Progressors showed increased urinary HMW-adiponectin at baseline (158[IQR41/479] vs. 65[24/168] ng/mol; p < 0.01), while total adiponectin (182[101/1534] vs. 345[118/1361] ng/mol) and AER (48[23/109] vs. 46[25/108] mg/24 h) excretion showed no differences between the groups. Multivariate logistic regression showed that HMW-adiponectin excretion was an independent predictor of renal progression in all patients (OR 1.86 [95 % CI 1.34-2.59]; p < 0.01), especially in those (n = 45) with normal AER at baseline (OR 2.16 [95 % CI 1.1-4.56]; p < 0.05). Urinary HMW-adiponectin but not AER improved the prediction of progressors in ROC analysis (AUC 0.72 [95 % CI 0.63-0.81] vs. 0.80 [95 % CI 0.71-0.90], p < 0.05). In conclusion, urinary HMW-adiponectin excretion may identify diabetes patients at increased risk for progression of kidney disease.
Collapse
Affiliation(s)
- Stefan Kopf
- Department of Medicine 1 and Clinical Chemistry, University Hospital Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany,
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Kusek M, Tokarski K, Hess G. Repeated restraint stress enhances glutamatergic transmission in the paraventricular nucleus of the rat hypothalamus. J Physiol Pharmacol 2013; 64:565-570. [PMID: 24304570] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/09/2013] [Accepted: 10/28/2013] [Indexed: 06/02/2023]
Abstract
Corticotropin-releasing hormone (CRH)-synthesizing parvocellular neuroendocrine neurons of the hypothalamic paraventricular nucleus (PVN) play a key role in the activation of the hypothalamic-pituitary-adrenal axis (HPA). It is well known that excitatory and inhibitory inputs that regulate the activity of these neurons may undergo stress-related modifications; however, the effect of repeated restraint stress on the function of glutamatergic and GABAergic synapses on PVN parvocellular neuroendocrine neurons has not been fully understood so far. Adolescent male Wistar rats were subjected to restraint lasting 10 min and repeated twice daily for 3 days. Brain slices were prepared 24 hours after the last restraint session and were studied ex vivo. Whole-cell patch-clamping was used to record spontaneous excitatory and inhibitory postsynaptic currents (sEPSCs and sIPSCs) from parvocellular neuroendocrine neurons of the PVN. Repeated restraint stress resulted in an increase in the mean frequency of sEPSCs and in a decrease in the rise time and the decay time constant of sEPSCs. There was no change in the mean amplitude of sEPSCs. The parameters characterizing sIPSCs also remained unaltered. In addition, the injected current vs. spiking rate ratio of parvocellular neurons was decreased. In conclusion, restraint stress, repeated for 3 days, selectively enhances excitatory synaptic inputs to parvocellular neurons of the PVN, these modifications being accompanied with a decrease in the intrinsic excitability of PVN neuroendocrine parvocellular neurons.
Collapse
Affiliation(s)
- M Kusek
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.
| | | | | |
Collapse
|
26
|
Kopf S, Oikonomou D, Zdunek D, von Eynatten M, Hess G, Nawroth P, Bierhaus A, Humpert P. Urinary n-acetyl-beta-d-glucosaminidase Excretion: an Indicator of Neuropathy in Type 2 Diabetes. Exp Clin Endocrinol Diabetes 2013; 121:601-6. [DOI: 10.1055/s-0033-1355384] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- S. Kopf
- Department of Medicine 1 and Clinical Chemistry of University Hospital Heidelberg, Germany
| | - D. Oikonomou
- Department of Medicine 1 and Clinical Chemistry of University Hospital Heidelberg, Germany
| | - D. Zdunek
- Roche Diagnostics GmbH, Mannheim, Germany
| | - M. von Eynatten
- Boehringer Ingelheim Pharma GmbH & Co. KG; Ingelheim am Rhein, Germany
| | - G. Hess
- Roche Diagnostics GmbH, Mannheim, Germany
| | - P. Nawroth
- Department of Medicine 1 and Clinical Chemistry of University Hospital Heidelberg, Germany
| | - A. Bierhaus
- Department of Medicine 1 and Clinical Chemistry of University Hospital Heidelberg, Germany
| | - P. Humpert
- Department of Medicine 1 and Clinical Chemistry of University Hospital Heidelberg, Germany
| |
Collapse
|
27
|
|
28
|
Krekeler G, Herzberg C, Dreyling M, Hess G, Kalanovic D. Evaluation of Safety, Tolerability and Efficacy of Temsirolimus in Patients with Relapsed or Refractory Mantle Cell Lymphoma (REL/REFR MCL) in the Usual Health Care Setting. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)33664-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
29
|
Nielsen SE, Persson F, Frandsen E, Sugaya T, Hess G, Zdunek D, Shjoedt KJ, Parving HH, Rossing P. Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study. Diabet Med 2012; 29:e184-90. [PMID: 22268920 DOI: 10.1111/j.1464-5491.2012.03585.x] [Citation(s) in RCA: 60] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
AIMS Adding aldosterone receptor blockade to standard renoprotective treatment may provide additional renoprotection in patients with overt nephropathy. We expected an impact of spironolactone in early diabetic nephropathy, and for this hypothesis we studied the effect on markers of glomerular and tubular damage in patients with Type 1 diabetes and persistent microalbuminuria. METHODS A double-blind, randomized, placebo-controlled crossover study in 21 patients with Type 1 diabetes and microalbuminuria using spironolactone 25 mg or placebo once daily, for 60 days added to standard antihypertensive treatment. After each treatment period, the primary endpoint were evaluated: urinary(u)-albumin excretion/24 hour(h) and secondary endpoints; 24 h blood pressure, glomerular filtration rate (GFR) and markers of tubular damage: urinary liver-type fatty-acid binding protein (LFABP), neutrophil gelatinase associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1). RESULTS All patients completed the study. During spironolactone treatment, urinary albumin excretion rate was reduced by 60% (range 21-80%), from 90 mg/24 h to 35 mg/24 h (P=0.01). Blood pressure (24 h) did not change during spironolactone treatment (P>0.2 for all comparisons). The GFR (SD) decreased from 78 (6) mL/min/1.73 m(2) to 72 (6) mL/min/1.73 m(2) (P=0.003). Urinary liver-type fatty-acid binding protein, neutrophil gelatinase-associated lipocalin and kidney injury molecule 1 did not change during treatment (P>0.3 for all comparisons). Treatment was well-tolerated, but two patients had severe hyperkalaemia (plasma potassium = 5.7 mmol/l), which was sufficiently treated with diuretics and dietary intervention. CONCLUSIONS Spironolactone treatment in addition to standard renoprotective treatment lowers urinary albumin excretion in microalbuminuric patients with Type 1 diabetes, and thus may offer additional renoprotection independent of blood pressure.
Collapse
Affiliation(s)
- S E Nielsen
- Steno Diabetes Center, Niels Steensens Vej, Gentofte, Denmark.
| | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Hill J, Cong Z, Hess G, McGarvey N, Nordyke R. Hemoglobin Decline in Chemotherapy Patients Prior to and after Policy Changes Affecting Use of Erythropoiesis-Stimulating Agents: 2006 – 2009. J Int Med Res 2012; 40:1532-45. [DOI: 10.1177/147323001204000433] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
OBJECTIVE: Since 2007, the use of erythropoiesis-stimulating agents (ESAs) to treat anemia in cancer patients receiving chemotherapy has been increasingly restricted in the USA. This study assessed hemoglobin (Hb) decline over time among chemotherapy patients. METHODS: Episodes of chemotherapy care were identified in a large US-oncology electronic medical record database; weekly Hb levels were computed in the first 8 weeks. Unadjusted and adjusted proportions of patient-weeks with Hb decline > 1 g/dl (i.e. representing clinically significant decline) within 1 or 2 weeks were analyzed. RESULTS: Between 2006 and 2009, unadjusted proportions of patient-weeks with Hb decline > 1 g/dl increased (1-week, from 12.7% to 14.9%; 2-week, from 19.3% to 26.3%). Adjusted 1-week proportions in 2007 were similar to 2006, but increased in 2008 (odds ratio [OR] 1.135; 95% confidence intervals [CI] 1.067, 1.208) and in 2009 (OR 1.235; 95% CI 1.094, 1.395). Adjusted 2-week proportions had the same pattern. CONCLUSIONS: Since restrictions on ESA use were introduced in the USA, more patients have experienced a clinically significant Hb decline after chemotherapy initiation. Initiating anemia therapy at the earliest indicated opportunity may help reduce the risk of such declines.
Collapse
Affiliation(s)
- Jw Hill
- IMS Health, Plymouth Meeting, Pennsylvania, USA
| | - Z Cong
- Amgen Inc., Thousand Oaks, California, USA
| | - G Hess
- IMS Health, Plymouth Meeting, Pennsylvania, USA
- Leonard Davis Institute, University of Pennsylvania, Philadelphia, Pennsylvania, USA
- Department of Health Policy, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - N McGarvey
- School of Public Health, University of California Los Angeles, Los Angeles, California, USA
| | - Rj Nordyke
- PriceSpective, Los Angeles, California, USA
| |
Collapse
|
31
|
Weber D, Faber-Heinemann G, Hess G, Hess E, Kaltheuner M, Krakow D, Lederle M, Molinski M, Reuter HM, Scheper N, Simonsohn M, Heinemann L. Klinische Wirksamkeit von DPP-4-Hemmern und GLP-1-Analoga bei 907 Patienten mit Typ 2 Diabetes mellitus in diabetologischen Schwerpunktpraxen. DIABETOL STOFFWECHS 2012. [DOI: 10.1055/s-0032-1314474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
32
|
Tokarski K, Kusek M, Hess G. Repeated blockade of 5-HT₇ receptors depresses glutamatergic transmission in the rat frontal cortex. J Physiol Pharmacol 2012; 63:173-177. [PMID: 22653904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/12/2012] [Accepted: 04/23/2012] [Indexed: 06/01/2023]
Abstract
The effects of the intraperitoneal administration of the 5-HT₇ receptor antagonist SB 269970 were studied in the rat frontal cortex. In ex vivo slices prepared from rats receiving 14 daily doses of the drug (1.25 mg/kg) the mean frequency and the mean amplitude of glutamate-mediated, spontaneous excitatory postsynaptic currents (sEPSCs) recorded from layer II/III pyramidal neurons, were decreased. In contrast, single administration of SB 269970 affected neither the frequency nor the amplitude of sEPSCs. Treatment with SB 269970 did not affect membrane excitability of pyramidal cells. These data indicate that repeated, but not single, treatment with SB 269970 results in an attenuation of glutamatergic transmission in the frontal cortex, most likely due to a combination of pre- and postsynaptic mechanisms.
Collapse
Affiliation(s)
- K Tokarski
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.
| | | | | |
Collapse
|
33
|
Tokarski K, Bobula B, Kusek M, Hess G. The 5-HT(7) receptor antagonist SB 269970 counteracts restraint stress-induced attenuation of long-term potentiation in rat frontal cortex. J Physiol Pharmacol 2011; 62:663-667. [PMID: 22314569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/07/2011] [Accepted: 11/30/2011] [Indexed: 05/31/2023]
Abstract
The effects of restraint lasting for 10 min, repeated twice daily for 3 days, were studied ex vivo in rat frontal cortex slices prepared 24 h after the last stress session. In slices originating from stressed animals, the amplitude of extracellular field potentials recorded in cortical layer II/III was increased. Stress also resulted in a reduced magnitude of long-term potentiation (LTP) of field potentials. In a separate experimental group, rats were subjected to restraint lasting for 10 min, twice daily for 3 days but, additionally, animals received injections of 5-HT(7) receptor antagonist SB 269970 (1.25 mg/kg) before each restraint stress session. In this group, the amplitude of field potentials and the magnitude of LTP were not different from the control, indicating that stress-induced modifications of basal glutamatergic transmission and synaptic plasticity were prevented by the 5-HT(7) receptor antagonist.
Collapse
Affiliation(s)
- K Tokarski
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.
| | | | | | | |
Collapse
|
34
|
Tokarski K, Kusek M, Hess G. 5-HT7 receptors modulate GABAergic transmission in rat hippocampal CA1 area. J Physiol Pharmacol 2011; 62:535-540. [PMID: 22204801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 08/24/2011] [Accepted: 10/04/2011] [Indexed: 05/31/2023]
Abstract
The effects of the activation of serotonin-7 (5-HT(7)) receptors were investigated in the CA1 area pyramidal cells and stratum radiatum fast spiking GABAergic interneurons of rat hippocampal slices. To activate 5-HT(7) receptors, 5-carboxamidotryptamine (5-CT), a nonselective 5-HT(1A)/5-HT(7) agonist, was applied in the presence of N-[2-[4-(2-methoxyphenyl)-1piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635), a selective 5-HT(1A) receptor antagonist. The activation of 5-HT(7) receptors resulted in a dose-dependent increase in the mean frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) recorded from pyramidal neurons while the mean amplitude of sIPSCs remained unaltered. A nonselective glutamate receptor antagonist, kynurenic acid, and voltage-gated sodium channel blocker, tetrodotoxin (TTX), attenuated but did not prevent the 5-HT(7) receptor-mediated increase of sIPSCs frequency in pyramidal cells. 5-CT application did not influence the excitability of stratum radiatum interneurons but it dose-dependently increased the mean frequency of spontaneous excitatory postsynaptic currents (sEPSCs) recorded from interneurons while the mean amplitude of sEPSCs remained unaltered. These data suggest that the activation of 5-HT(7) receptors results in an enhancement of the GABAergic transmission in the hippocampal CA1 area via two mechanisms. The first one involves an enhancement of excitatory glutamatergic input to GABAergic interneurons and is likely to be mediated by presynaptic 5-HT(7) receptors. The second effect, most likely related to the activation of 5-HT(7) receptors located on interneurons, results in an enhancement of the release of GABA.
Collapse
Affiliation(s)
- K Tokarski
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Cracow, Poland.
| | | | | |
Collapse
|
35
|
Bair A, Hess G, Boni J, Offner F. Randomized phase IV trial comparing efficacy and tolerability of temsirolimus with and without an elevated starting dose in patients with relapsed, refractory mantle cell lymphoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps222] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
36
|
Weber D, Kaltheuner M, Scheper C, Hübbenet JV, Heckermann S, Reichert D, Hess E, Hess G, Krakow D, Lederle M, Molinski M, Nitzsche G, Reuter HM, Simonsohn M, Heinemann L, Faber-Heinemann G. Evaluierung der Morbiditäten und Co-Morbiditäten von Patienten mit Diabetes, die in diabetologischen Schwerpunkt-Praxen behandelt werden. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
37
|
Hess G, Hess E, Weber D, Scheper C, Kaltheuner M, Molinski M, Krakow D, Reuter HM, Nitzsche G, Simonsohn M, Lederle M, Hübbenet JV, Faber-Heinemann G, Heinemann L. Charakteristika von 833 Patienten, die neu mit GLP-1-Analoga oder DPP-IV Inhibitoren in 38 Diabetes-Schwerpunktpraxen therapiert werden. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
38
|
Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G. Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland. Oncology 2011; 79:247-54. [PMID: 21372599 DOI: 10.1159/000322866] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2010] [Accepted: 10/08/2010] [Indexed: 11/19/2022]
Abstract
OBJECTIVES This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment. METHODS Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed. RESULTS Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤ 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely. CONCLUSIONS These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
Collapse
Affiliation(s)
- I Hrusovsky
- Diakonie-Krankenhaus, Schwäbisch Hall, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Grünhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, Jäger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, Bühler A, Winkler D, Zenz T, Böttcher S, Ritgen M, Mendila M, Kneba M, Döhner H, Stilgenbauer S. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010; 376:1164-74. [PMID: 20888994 DOI: 10.1016/s0140-6736(10)61381-5] [Citation(s) in RCA: 1269] [Impact Index Per Article: 90.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
BACKGROUND On the basis of promising results that were reported in several phase 2 trials, we investigated whether the addition of the monoclonal antibody rituximab to first-line chemotherapy with fludarabine and cyclophosphamide would improve the outcome of patients with chronic lymphocytic leukaemia. METHODS Treatment-naive, physically fit patients (aged 30-81 years) with CD20-positive chronic lymphocytic leukaemia were randomly assigned in a one-to-one ratio to receive six courses of intravenous fludarabine (25 mg/m(2) per day) and cyclophosphamide (250 mg/m(2) per day) for the first 3 days of each 28-day treatment course with or without rituximab (375 mg/m(2) on day 0 of first course, and 500 mg/m(2) on day 1 of second to sixth courses) in 190 centres in 11 countries. Investigators and patients were not masked to the computer-generated treatment assignment. The primary endpoint was progression-free survival (PFS). Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00281918. FINDINGS 408 patients were assigned to fludarabine, cyclophosphamide, and rituximab (chemoimmunotherapy group) and 409 to fludarabine and cyclophosphamide (chemotherapy group); all patients were analysed. At 3 years after randomisation, 65% of patients in the chemoimmunotherapy group were free of progression compared with 45% in the chemotherapy group (hazard ratio 0·56 [95% CI 0·46-0·69], p<0·0001); 87% were alive versus 83%, respectively (0·67 [0·48-0·92]; p=0·01). Chemoimmunotherapy was more frequently associated with grade 3 and 4 neutropenia (136 [34%] of 404 vs 83 [21%] of 396; p<0·0001) and leucocytopenia (97 [24%] vs 48 [12%]; p<0·0001). Other side-effects, including severe infections, were not increased. There were eight (2%) treatment-related deaths in the chemoimmunotherapy group compared with ten (3%) in the chemotherapy group. INTERPRETATION Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab improves progression-free survival and overall survival in patients with chronic lymphocytic leukaemia. Moreover, the results suggest that the choice of a specific first-line treatment changes the natural course of chronic lymphocytic leukaemia. FUNDING F Hoffmann-La Roche.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Antineoplastic Combined Chemotherapy Protocols/therapeutic use
- Cyclophosphamide/administration & dosage
- Disease Progression
- Disease-Free Survival
- Drug Administration Schedule
- Female
- Humans
- Immunologic Factors/administration & dosage
- Incidence
- Kaplan-Meier Estimate
- Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy
- Leukemia, Lymphocytic, Chronic, B-Cell/mortality
- Leukopenia/chemically induced
- Male
- Middle Aged
- Neutropenia/chemically induced
- Rituximab
- Severity of Illness Index
- Treatment Outcome
- Vidarabine/administration & dosage
- Vidarabine/analogs & derivatives
Collapse
Affiliation(s)
- M Hallek
- Department I of Internal Medicine and Centre for Integrated Oncology, University of Cologne, Cologne, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Czuczman MS, Viardot A, Hess G, Gadeberg OV, Pedersen LM, Gupta I, Lin TS, Strange C, Windfeld K, Russell CA. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8042] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
41
|
Haioun C, Morschhauser F, Jourdan E, Karsenti J, Hess G, Duehrsen U, Kravchenko S, van Hal G, Hahka-Kemppinen M. Preliminary results of a phase II study of rituximab (R), gemcitabine (Gem), oxaliplatin (Ox) plus enzastaurin (ENZ) followed by ENZ maintenance as salvage regimen for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.8069] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
42
|
von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest 2010; 40:95-102. [PMID: 19912308 DOI: 10.1111/j.1365-2362.2009.02220.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
BACKGROUND Urinary liver-type fatty acid binding protein (L-FABP) and kidney injury molecule (KIM)-1, novel urinary biomarkers of renal tubulointerstitial function, have previously been associated with acute ischaemic kidney injury. We studied the clinical significance of urinary L-FABP, KIM-1 and N-acetyl-beta-glucosaminidase (NAG) as potential markers of renal function and chronic ischaemic injury in patients with diabetic nephropathy. MATERIAL AND METHODS A total of 130 type 2 diabetes patients with early diabetic nephropathy and 40 healthy controls were studied. Urinary L-FABP, KIM-1, NAG, albumin excretion rate (AER) and creatinine clearance were obtained from 24-h urine samples, and correlated with measures of red blood cell count, renal function and metabolic control. RESULTS Urinary L-FABP was significantly increased in diabetes patients compared with healthy controls [8.1 (interquartile 0.6-11.6) vs. 2.4 (0.5-3.6) microg/g creatinine, P < 0.001] and correlated with AER (r = 0.276, P = 0.002), creatinine clearance (r = -0.189, P = 0.033) and haemoglobin levels (r = -0.190, P = 0.030). In multivariable linear regression analysis, haemoglobin (beta = -0.247, P = 0.015) and AER (beta = 0.198, P = 0.046) were significant predictors of urinary L-FABP. Prevalent anaemia was independently associated with a 6-fold risk for increased tubulointerstitial kidney damage (upper vs. lower two L-FABP tertiles: OR, 6.06; 95% CI: 1.65-22.23; P = 0.007). Urinary KIM-1 was not significantly associated with kidney function, AER, or measures of red blood cell count while urinary NAG was associated with parameters of glucose control and renal function. CONCLUSIONS Different urinary biomarkers may reflect distinct pathophysiological mechanisms of tubulointerstitial damage in early diabetic nephropathy: Urinary L-FABP could be a novel biomarker for chronic intrarenal ischaemia.
Collapse
|
43
|
Grzegorzewska M, Maćkowiak M, Wedzony K, Hess G. 5-HT1A receptors mediate detrimental effects of cocaine on long-term potentiation and expression of polysialylated neural cell adhesion molecule protein in rat dentate gyrus. Neuroscience 2009; 166:122-31. [PMID: 20006974 DOI: 10.1016/j.neuroscience.2009.12.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2009] [Revised: 11/19/2009] [Accepted: 12/05/2009] [Indexed: 01/11/2023]
Abstract
The present study investigated the involvement of 5-HT(1A) receptors in the inhibitory effect of single administration of cocaine (COC, 15 mg/kg i.p.) on the induction of long-term potentiation (LTP) in slices of rat dentate gyrus (DG), prepared 30 min and 2 days after COC administration. These effects of COC were blocked by an antagonist of 5-HT(1A) receptors, WAY 100635 (0.4 mg/kg i.p.), which had been administered 20 min before COC. The detrimental effect of COC on LTP in slices prepared 30 min after COC administration could be prevented by blocking glucocorticoid receptors (GRs) using mifepristone (RU 38486, 10 mg/kg s.c. given 1 h before COC), similar as in slices obtained 2 days after COC as reported previously [Maćkowiak et al. (2008) Eur J Neurosci 27:2928-2937]. After a single administration of an agonist of 5-HT(1A) receptors, 8-OH-DPAT, (0.5 mg/kg i.p.), the level of LTP in slices prepared 2 days later was significantly decreased resembling the effect of COC. This effect of 8-OH-DPAT was antagonized by WAY 100635 (0.4 mg/kg i.p.), administered 20 min before 8-OH-DPAT and by RU 38486, given 1 h before 8-OH-DPAT. COC-induced inhibition of LTP could be blocked by the inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2), SL 327 (50 mg/kg i.p.), administered 1 h before COC, but not by the inhibitor of phosphatidylinositol 3-kinase (PI3-kinase), LY 294002 (80 mg/kg i.p.). COC-induced reduction in the number of polysialylated neural cell adhesion molecule (PSA-NCAM)-positive neurons in rat dentate gyrus could also be prevented by WAY 100635, given 20 min before COC. These data indicate that the indirect 5-HT(1A) receptor activation by a single COC administration and subsequent stimulation of extracellular signal-regulated kinases (ERK 1/2) signaling pathway result in a decrease of the potential for long-term increase in synaptic efficacy in rat DG lasting at least two but less than 7 days, most likely via activation of the hypothalamic-pituitary-adrenal (HPA) axis.
Collapse
Affiliation(s)
- M Grzegorzewska
- Department of Physiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, 31-343 Kraków, Poland
| | | | | | | |
Collapse
|
44
|
Abstract
OBJECTIVE To compare the incidence of Alzheimer disease and related disorders (ADRD) in patients treated with IV immunoglobulin (IVIg) for non-Alzheimer disease (AD) indications vs untreated controls. METHODS This retrospective case-control analysis used medical claims for patients > or =65 years old from a national database of 20 million age-qualified patients. Cases received > or =1 IVIg administration during April 1, 2001-August 31, 2004, had claims 1 year prior to first (index) IVIg administration to confirm absence of pre-index ADRD, and had > or =3 years of continuous claims post-index. Untreated controls had their first medical claim during April 1, 2000-August 31, 2004, and otherwise met the same requirements as cases. Controls were matched 100:1 to cases on age, gender, and risk factors for ADRD. The relative incidence of ADRD post-index for the IVIg-treated cases vs untreated controls was estimated using Kaplan-Meier survival curves and a Cox proportional hazards model. RESULTS Treated patients in the Kaplan-Meier analysis had lower ADRD incidence (p = 0.02) with an estimated 2.6% of the 847 IVIg-treated vs 4.6% of 84,700 controls diagnosed with ADRD at 60 months after index date. Treated patients in the Cox proportional hazard model had a 42% lower risk of being diagnosed with ADRD (hazard ratio, 0.577; 95% confidence interval, 0.359 to 0.930; p = 0.024) with an estimated 2.8% of treated vs 4.8% of controls diagnosed with ADRD at 60 months after index date. CONCLUSIONS Previous treatment with IV immunoglobulin was associated with a reduced risk of developing Alzheimer disease and related disorders (ADRD) in this study. Evidence from additional studies is needed to evaluate the relationship between IVIg exposure and ADRD diagnosis.
Collapse
Affiliation(s)
- H Fillit
- Alzheimer's Drug Discovery Foundation, New York, NY, USA
| | | | | | | | | |
Collapse
|
45
|
Tokarski K, Pitra P, Duszynska B, Hess G. Imipramine counteracts corticosterone-induced alterations in the effects of the activation of 5-HT(7) receptors in rat hippocampus. J Physiol Pharmacol 2009; 60:83-88. [PMID: 19617650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 10/01/2008] [Accepted: 04/30/2009] [Indexed: 05/28/2023]
Abstract
Using extracellular recording we studied changes in the reactivity of rat hippocampal slices to an agonist of the 5-HT(7) receptor, 5-carboxamidotryptamine (5-CT; 0.025-1 microM), induced by an earlier treatment of animals with corticosterone. Spontaneous bursting activity was recorded in ex vivo slices incubated in the presence of 2-[4-(2-methoxyphenyl)-1piperazinyl]ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635; 2 microM), an antagonist of the 5-HT(1A) receptor, in the medium devoid of Mg2+ ions. Saturation binding assays were performed using [(3)H]-(2R)-1-[(3-hydroxyphenyl)sulfonyl]-2-[2-(4-methyl-1-piperidinyl)ethyl]pyrrolidine hydrochloride (SB 269970), a specific antagonist of the 5-HT(7) receptor. Repetitive, but not single, corticosterone administration lasting 7 and 21 days, resulted in an enhancement of the effect related to the 5-HT(7) receptor activation without changes in its binding properties. In a separate set of experiments rats were treated with corticosterone for 3 weeks and additionally with imipramine, beginning on the eighth day of corticosterone administration. In the corticosterone plus imipramine group the excitatory effect of 5-CT was weaker than in the corticosterone group, indicating that corticosterone-induced functional modifications in the reactivity of the 5-HT(7) receptor were reversed and further weakened by imipramine treatment. This effect was accompanied by a reduction in the density of [3H]-SB 269970 binding sites. Thus, imipramine treatment counteracts the corticosterone-induced increase in the reactivity of the hippocampal circuitry to the activation of the 5-HT(7) receptor.
Collapse
Affiliation(s)
- K Tokarski
- Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
| | | | | | | |
Collapse
|
46
|
Lalla D, Hess G, Quach D, Brammer M, Hill JW. A retrospective study evaluating treatment patterns and outcomes in patients receiving trastuzumab for treatment of first-line and second-line metastatic breast cancer (mBC). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e12008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e12008 Background: Practice patterns for patients with MBC following 1st line therapy have often continued trastuzumab treatments while changing other chemotherapeutic agents in the regimen. We described treatment patterns, switching patterns and progression in mBC patients treated with a trastuzumab containing regimen for 1st and second line mBC. Methods: A retrospective, longitudinal, observational study of patients with mBC during 1/1/2003 up to 6/30/2008. The dataset comprised 304,654 cancer patients from 91practice sites across 23 states using Varian or Impac electronic medical records (EMRs). The start and end of a line of therapy was defined by a regimen change or a > 42 day gap in the regimen. In addition to the database analyses, a manual chart review was also conducted for 20% of the study sample to validate the source data and results. Patients were required to be observed for ≥ 9 months from index. Mean, median, standard deviation, and standard error for the duration in days by line and regimen was calculated as well as an overall weighted mean by line. Results: The study sample of 239 patients post-mBC was treated with the following regimens in the Table. Conclusion: Trastuzumab is most frequently given with taxanes in the first and second line settings. In the second line trastuzumab monotherapy, vinorelbine and gemcitabine were also frequently used. First line therapy may influence the selection of second line therapy. As EMRs often reflect care primarily at the practice site, prescribing of oral agents should be further researched. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. Lalla
- Genentech, Inc., South San Francisco, CA; SDI/University of Pennsylvania, Plymouth Meeting, PA; SDI Health LLC, Plymouth Meeting, PA
| | - G. Hess
- Genentech, Inc., South San Francisco, CA; SDI/University of Pennsylvania, Plymouth Meeting, PA; SDI Health LLC, Plymouth Meeting, PA
| | - D. Quach
- Genentech, Inc., South San Francisco, CA; SDI/University of Pennsylvania, Plymouth Meeting, PA; SDI Health LLC, Plymouth Meeting, PA
| | - M. Brammer
- Genentech, Inc., South San Francisco, CA; SDI/University of Pennsylvania, Plymouth Meeting, PA; SDI Health LLC, Plymouth Meeting, PA
| | - J. W. Hill
- Genentech, Inc., South San Francisco, CA; SDI/University of Pennsylvania, Plymouth Meeting, PA; SDI Health LLC, Plymouth Meeting, PA
| |
Collapse
|
47
|
Hulnick SA, Hess G, Hill J, Viswanathan HN, Nordyke RJ. Erythropoiesis stimulating agent (ESA) administration at Hb <10 g/dL for chemotherapy-induced anemia (CIA) following the National Coverage Decision (NCD). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20627] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20627 Background: Medicare coverage of ESA treatment for CIA was changed in 7/07 to a hemoglobin (Hb) < 10 g/dL prior to administration. We describe the proportion of ESA administrations at Hb < 10 g/dL over four quarters following the NCD. Methods: A retrospective analysis of ESA administrations from 7/07 - 6/08 using Varian and Impac electronic medical records for 304,654 cancer patients from 91 practice sites across 19 states. Episodes of ESA treatment were identified within chemotherapy episodes. A > 42 day gap in ESA use identified a completed ESA episode and a > 90 day gap in chemotherapy identified a chemotherapy episode. Hb ≤ 7 days prior to ESA administration date was identified for each ESA episode. The percent of ESA administrations at Hb < 10 g/dL was measured from Q3 07 to Q2 08 for darbepoetin alfa (DA) and epoetin alfa (EA) stratified by age. Results: For patients age ≥ 65, the percent of ESAs administered at Hb < 10 g/dL increased from Q3 07 to Q2 08 for initial and maintenance administrations. A less pronounced trend was observed in patients age < 65. Maintenance administrations at Hb < 10 g/dL in patients age < 65 were significantly lower for EA vs. DA. Conclusions: ESA administrations have been increasingly administered at Hb < 10 g/dL. A higher proportion of Medicare-eligible patients received maintenance ESA administrations at Hb < 10 g/dL. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- S. A. Hulnick
- Surveillance Data, Inc., Plymouth Meeting, PA; SDI, Leonard Davis Inst, U Penn, Plymouth Meeting, PA; Amgen, Inc., Thousand Oaks, CA
| | - G. Hess
- Surveillance Data, Inc., Plymouth Meeting, PA; SDI, Leonard Davis Inst, U Penn, Plymouth Meeting, PA; Amgen, Inc., Thousand Oaks, CA
| | - J. Hill
- Surveillance Data, Inc., Plymouth Meeting, PA; SDI, Leonard Davis Inst, U Penn, Plymouth Meeting, PA; Amgen, Inc., Thousand Oaks, CA
| | - H. N. Viswanathan
- Surveillance Data, Inc., Plymouth Meeting, PA; SDI, Leonard Davis Inst, U Penn, Plymouth Meeting, PA; Amgen, Inc., Thousand Oaks, CA
| | - R. J. Nordyke
- Surveillance Data, Inc., Plymouth Meeting, PA; SDI, Leonard Davis Inst, U Penn, Plymouth Meeting, PA; Amgen, Inc., Thousand Oaks, CA
| |
Collapse
|
48
|
Eynatten MV, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, Bierhaus A, Humpert PM. Klinische Wertigkeit zweier neuartiger Urinbiomarker bei Patienten mit diabetischer Nephropathie. DIABETOL STOFFWECHS 2009. [DOI: 10.1055/s-0029-1221818] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Hess G, Müler B. [FlexPen--light handling nd high dosage accuracy. A ready pen for almost all insulins]. MMW Fortschr Med 2009; 151:44-45. [PMID: 19472668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
|
50
|
Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2008; 23:153-61. [PMID: 18818699 DOI: 10.1038/leu.2008.261] [Citation(s) in RCA: 129] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Lymphoplasmacytic lymphoma (LPL) is an indolent lymphoma with moderate sensitivity to conventional chemotherapy. This study investigated whether the addition of rituximab to standard chemotherapy improves treatment outcome in LPL and the subgroup of LPL patients fulfilling the criteria of Waldenstroem's macroglobulinemia (WM). A total of 69 patients with previously untreated LPL were enrolled into the trial; 64 patients were evaluable for treatment outcome. In all, 48 of the 64 LPL patients fulfilled the criteria of WM. Patients were randomly assigned to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, n=34) or CHOP (n=30). R-CHOP resulted in significantly higher overall response (OR) rate (94 vs 67%, P=0.0085) in the LPL patients and in the WM subgroup (91 vs 60%, P=0.0188). With a median observation time of 42 months, R-CHOP induced a significantly longer time to treatment failure (TTF) with a median of 63 months for R-CHOP vs 22 months in the CHOP arm in the LPL patients (P=0.0033) and in the WM subgroup (P=0.0241). There was no major difference of treatment-associated toxicity between both treatment groups. These data indicate that the addition of rituximab to front-line chemotherapy improves treatment outcome in patients with LPL or WM.
Collapse
Affiliation(s)
- C Buske
- Department of Internal Medicine III, University of Munich, Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|